trending Market Intelligence /marketintelligence/en/news-insights/trending/q1xPW5dvWuS_s10jeJgpDQ2 content esgSubNav
In This List

Biopharma firm Transcenta raises US$100M in financing round

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Biopharma firm Transcenta raises US$100M in financing round

Chinese biopharmaceutical firm Transcenta Holding Ltd. raised US$100 million in a series B+ financing round.

New investors CR-CP Life Sciences Fund, Fortune Venture Capital Co. Ltd., Epiphron Capital, CCT China Merchant Buyout Fund, and China Equity Group participated in the round alongside existing shareholders Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners LP, Sequoia Capital China, and Arch Venture Partners LP.

Transcenta was formed in January 2019 following the merger between MabSpace Biosciences in Hong Kong and HJB, which has sites in China and the U.S.